Evidence map›Paper›PMID 39917490›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025

Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients.

Süreyya Yiğit Kaya, Yaşa Gül Mutlu, Orhan Kemal Yücel, İlknur Nizam Özen, Ünal Ataş, Elif Melek, Senem Maral, Volkan Karakuş, Leylagül Kaynar, Ömür Gökmen Sevindik

Abstract read
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Süreyya Yiğit KayaDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0001-6732-8068
Yaşa Gül MutluDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0003-1508-2822
Orhan Kemal YücelDepartment of Hematology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0002-0455-1382
İlknur Nizam ÖzenDepartment of Hematology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID 0000-0002-7787-2232
Ünal AtaşDepartment of Hematology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0001-5897-6514
Elif MelekDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0002-9005-5587
Senem MaralDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0003-4766-1861
Volkan KarakuşDepartment of Hematology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID 0000-0001-9178-2850
Leylagül KaynarDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0002-2035-9462
Ömür Gökmen SevindikDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0001-9636-4113

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the efficacy and safety of generic plerixafor (Pleksor - Gen Pharma) compared to the original plerixafor (Mozobil - Sanofi) in patients with multiple myeloma undergoing ASCT. A total of 59 patients from three centers, who underwent ASCT between 2018 and 2023, were included and divided into two groups: Mozobil (M) group (

Indexed as

GenericMobilizationMultiple myelomaPlerixaforStem cell

Identifiers

PMID39917490
PMCPMC11794722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.